MARKET

NEUP

NEUP

Neuphoria Therapeutics Inc
NASDAQ
4.270
+0.080
+1.91%
Closed 17:47 12/04 EST
OPEN
4.180
PREV CLOSE
4.190
HIGH
4.300
LOW
4.148
VOLUME
74.33K
TURNOVER
--
52 WEEK HIGH
21.40
52 WEEK LOW
2.900
MARKET CAP
22.96M
P/E (TTM)
-1.1341
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)
TipRanks · 5h ago
Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
TipRanks · 5h ago
NEUPHORIA THERAPEUTICS INC. <NEUP.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $21
Reuters · 5h ago
Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
TipRanks · 1d ago
NEUPHORIA RESPONDS TO LYNX1’S REVISED INDICATION OF INTEREST AT A REDUCED PRICE AND PREMIUM
Reuters · 1d ago
NEUPHORIA THERAPEUTICS INC - PAUSES R&D EXPENDITURES FOR BNC210 IN PTSD & IS EVALUATING ALL POSSIBILITIES AS PART OF THE CO'S STRATEGIC REVIEW
Reuters · 1d ago
NEUPHORIA THERAPEUTICS INC - URGES STOCKHOLDERS TO VOTE "FOR" BOTH OF NEUPHORIA'S NOMINEES ON WHITE PROXY CARD
Reuters · 1d ago
Neuphoria Therapeutics 13D Filing Shows Lynx1 Capital Management LP Boosts Stake To 16.3% And Submits Revised $4.75-Per-Share Buyout Proposal For Neuphoria Therapeutics
Benzinga · 3d ago
More
About NEUP
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Webull offers Neuphoria Therapeutics Inc stock information, including NASDAQ: NEUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEUP stock methods without spending real money on the virtual paper trading platform.